story of the week
Patients Prefer Subcutaneous Trastuzumab Administration in HER2-Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patients' Preference of Trastuzumab Administration (Subcutaneous Versus Intravenous) in HER2-Positive Metastatic Breast Cancer: Results of the Randomised MetaspHer Study
Eur. J. Cancer 2017 Jun 24;[EPub Ahead of Print], X Pivot, JP Spano, M Espie, P Cottu, C Jouannaud, V Pottier, L Moreau, JM Extra, A Lortholary, P Rivera, D Spaeth, H Attar-Rabia, C Benkanoun, L Dima-Martinez, N Esposito, J GligorovFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.